La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Tianjin Chase Sun PharmaceuticalLtd Performance dei guadagni passati
Il passato criteri di controllo 1/6
Tianjin Chase Sun PharmaceuticalLtd has been growing earnings at an average annual rate of 12.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 6.7% per year. Tianjin Chase Sun PharmaceuticalLtd's return on equity is 4.2%, and it has net margins of 6.6%.
Informazioni chiave
12.1%
Tasso di crescita degli utili
11.9%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 10.9% |
| Tasso di crescita dei ricavi | 6.7% |
| Rendimento del capitale proprio | 4.2% |
| Margine netto | 6.6% |
| Prossimo aggiornamento sui guadagni | 30 Aug 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well
Aug 02
There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings
Jun 12Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03
May 22This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts
May 21Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04Ripartizione dei ricavi e delle spese
Come Tianjin Chase Sun PharmaceuticalLtd guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 24 | 5,913 | 389 | 2,450 | 204 |
| 31 Dec 23 | 6,109 | 507 | 2,515 | 210 |
| 30 Sep 23 | 6,672 | 663 | 2,826 | 209 |
| 30 Jun 23 | 6,762 | 617 | 2,971 | 220 |
| 31 Mar 23 | 6,577 | 561 | 2,859 | 229 |
| 01 Jan 23 | 6,650 | 624 | 2,807 | 231 |
| 30 Sep 22 | 7,084 | 521 | 3,026 | 257 |
| 30 Jun 22 | 7,496 | 602 | 3,099 | 231 |
| 31 Mar 22 | 7,764 | 732 | 3,133 | 207 |
| 31 Dec 21 | 7,671 | 687 | 3,128 | 197 |
| 30 Sep 21 | 7,266 | 611 | 2,837 | 197 |
| 30 Jun 21 | 7,192 | 667 | 2,846 | 198 |
| 31 Mar 21 | 7,001 | 657 | 2,811 | 195 |
| 31 Dec 20 | 6,488 | 573 | 2,717 | 177 |
| 30 Sep 20 | 6,109 | 485 | 2,708 | 161 |
| 30 Jun 20 | 5,497 | 396 | 2,565 | 161 |
| 31 Mar 20 | 5,085 | 337 | 2,553 | 174 |
| 31 Dec 19 | 5,003 | 403 | 2,534 | 179 |
| 30 Sep 19 | 4,796 | 264 | 2,513 | 166 |
| 30 Jun 19 | 4,548 | 216 | 2,412 | 161 |
| 31 Mar 19 | 4,303 | 219 | 2,267 | 143 |
| 31 Dec 18 | 4,224 | 211 | 2,210 | 141 |
| 30 Sep 18 | 4,015 | 463 | 2,016 | 126 |
| 30 Jun 18 | 3,894 | 514 | 1,876 | 161 |
| 31 Mar 18 | 3,605 | 485 | 1,713 | 134 |
| 31 Dec 17 | 3,374 | 451 | 1,618 | 109 |
| 30 Sep 17 | 3,543 | 633 | 1,694 | 70 |
| 30 Jun 17 | 3,564 | 630 | 1,818 | 0 |
| 31 Mar 17 | 3,743 | 666 | 1,982 | 0 |
| 31 Dec 16 | 3,867 | 659 | 2,100 | 0 |
| 30 Sep 16 | 3,722 | 582 | 2,211 | 0 |
| 30 Jun 16 | 3,635 | 599 | 2,195 | 0 |
| 31 Mar 16 | 3,596 | 572 | 2,237 | 0 |
| 31 Dec 15 | 3,348 | 535 | 2,153 | 0 |
| 30 Sep 15 | 3,187 | 541 | 1,988 | 0 |
| 30 Jun 15 | 3,076 | 474 | 1,961 | 0 |
| 31 Mar 15 | 2,969 | 452 | 1,922 | 0 |
| 31 Dec 14 | 2,864 | 447 | 1,860 | 0 |
| 30 Sep 14 | 2,681 | 421 | 1,756 | 0 |
| 30 Jun 14 | 2,405 | 395 | 1,562 | 0 |
| 31 Mar 14 | 2,201 | 362 | 1,418 | 0 |
| 31 Dec 13 | 2,097 | 340 | 1,349 | 0 |
| 30 Sep 13 | 1,862 | 308 | 1,174 | 0 |
Guadagni di qualità: 300026 has a large one-off gain of CN¥151.1M impacting its last 12 months of financial results to 31st March, 2024.
Margine di profitto in crescita: 300026's current net profit margins (6.6%) are lower than last year (8.5%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 300026's earnings have grown by 12.1% per year over the past 5 years.
Accelerare la crescita: 300026's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Guadagni vs Settore: 300026 had negative earnings growth (-30.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Rendimento del capitale proprio
ROE elevato: 300026's Return on Equity (4.2%) is considered low.